Clinical data | |
---|---|
Pronunciation | /ɛˈzɛtɪmɪb, -maɪb/ |
Trade names | Zetia, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a603015 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Cholesterol absorption inhibitor |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 35% to 65% |
Protein binding | >90% |
Metabolism | Intestinal wall, liver |
Elimination half-life | 19 h to 30 h |
Excretion | Kidney 11%, fecal 78% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.207.996 |
Chemical and physical data | |
Formula | C24H21F2NO3 |
Molar mass | 409.433 g·mol−1 |
3D model (JSmol) | |
Melting point | 164 to 166 °C (327 to 331 °F) |
| |
| |
(verify) |
Ezetimibe, sold under the brand name Zetia among others, is a medication used to treat high blood cholesterol and certain other lipid abnormalities.[3][4] Generally it is used together with dietary changes and a statin.[5] Alone, it is less preferred than a statin.[4] It is taken by mouth.[4] It is also available in the fixed-dose combinations ezetimibe/simvastatin,[6] ezetimibe/atorvastatin,[7] ezetimibe/rosuvastatin,[4][8] and ezetimibe/bempedoic acid.[9]
The most commonly reported adverse events include upper respiratory tract infections, joint pain, diarrhea, and tiredness.[4] Serious side effects may include anaphylaxis, liver problems, depression, and muscle breakdown.[4][5] Use in pregnancy and breastfeeding is of unclear safety.[10] Ezetimibe works by decreasing cholesterol absorption in the intestines.[5]
Ezetimibe was approved for medical use in the United States in 2002.[4] It is available as a generic medication.[5] In 2022, it was the 79th most commonly prescribed medication in the United States, with more than 8 million prescriptions.[11][12]